Clinical Trial

Bag CPAP vs Standard Oxygen Therapy in Acute Hypoxemic Respiratory Failure

Study acronym: BAGCPAP-R
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Acute Hypoxemic Respiratory Failure (AHRF) is one of the prevalent causes of admission around the world and is associated with high mortality in resource-limited settings. Limited access to invasive mechanical ventilation is among the contributing factors to poor outcomes. The Bag CPAP may be useful in reducing the need for intubation and therefore mortality in patients with AHRF but data are lacking. This study aims to determine whether the Bag CPAP compared to standard oxygen care, could reduce the percentage of patients with criteria for intubation in patients with AHRF. This is a prospective randomized, open-label, controlled trial in which patients presenting at the emergency room in Rwanda will be randomly assigned to receive standard oxygen therapy or Bag CPAP. The primary endpoint is the percentage of patients with criteria for intubation at day 7. Secondary endpoints include the tolerance of the Bag CPAP, overall 28-day mortality rate, mortality rate of intubated patients on mechanical ventilation at day 28, percentage of patients intubated at 28 days, ventilator-free days at day 28, interval between the initiation of treatment and the onset of intubation criteria, the interval between the time when criteria for intubation are met and intubation, organ failure-free days at day 7 and length of hospital stay.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-03.
Trial Details
NCT Number NCT07460427
Lead Sponsor Prof RWABIHAMA Jean Paul
Conditions Acute Hypoxemic Respiratory Failure
Enrollment 250 participants
Start Date 2026-04-20
Primary Completion 2027-02-20 (estimated)
Study Completion 2027-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-19